Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Health Plan step therapy Coverage | Ope…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy N/A

    Step therapy criteria for pharmacy-covered drugs

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy (prior authorization and step requirements) for various pharmacy and specialty drugs covered under Providence Health Plan's pharmacy benefit; applies to providers prescribing these medications for plan members.

    Policy Summary
    PayerProvidence Health Plan
    PolicyStep therapy criteria for pharmacy-covered drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionVerify prior authorization and submit required documentation per plan procedures when prescribing drugs listed on the step therapy criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleclasses listed
    dozensitems listed
    2026-07-01last revised

    Coverage criteria overview

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Step therapy applicability — general

    Drugs enumerated in this document are subject to Providence Health Plan step therapy rules; specific step sequences, required trials, durations, and failure definitions are not detailed in the provided text and must be verified via the plan's Drug Search tool or full policy details.

    listed_drug: Member is prescribed a drug that appears on this step therapy listing (any drug or formulation enumerated in the policy)

    This document lists multiple drug classes and specific formulations (for example: antiepileptic agents such as perampanel/FYCOMPA, eslicarbazepine/APTIOM, brivaracetam/BRIVIACT, rufinamide/BANZEL, cenobamate/XCOPRI; glaucoma agents including bimatoprost, tafluprost, VYZULTA; stimulatory factors/G-CSF products; phosphate binders such as AURYXIA, VELPHORO, lanthanum, sevelamer; topical agents such as ivermectin/SOOLANTRA; and others). Providers must confirm plan-specific step requirements for the listed drug.

    Drugs enumerated in this document are subject to Providence Health Plan step therapy criteria when covered under the pharmacy benefit. The listing groups multiple drug classes and specific formulations that may be subject to step requirements; however, specific step sequences, required trials, durations, and failure definitions are not provided in the excerpt. Providers must consult the plan’s full policy and formulary tools (for example, the online Drug Search) to determine the precise step-therapy requirements that apply to a particular drug and member.

    The provided document excerpt does not include an explicit list of conditions or situations designated as not medically necessary for the drugs covered by these step therapy criteria. Additionally, the policy states that additional restrictions and exclusions to drug coverage may apply, and that coverage is not guaranteed — providers and members should verify benefits via the Drug Search tool, the member handbook, or by contacting Providence Customer Service.

    Listed drug formulations and code groups

    Listed drug formulations (partial extract)NDC | mixed
    perampanel oral suspension 0.5 mg/mllisted formulation
    perampanel oral tablet 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mglisted formulations
    FYCOMPA ORAL SUSPENSION 0.5 MG/MLlisted formulation
    FYCOMPA ORAL TABLET 2 MG, 4 MG, 6 MG, 8 MG, 10 MG, 12 MGlisted formulations
    eslicarbazepine oral tablet 200 mg, 400 mg, 600 mg, 800 mglisted formulations (APTIOM)
    brivaracetam oral solution 10 mg/mlBRIVIACT oral solution
    rufinamide oral suspension 40 mg/mlBANZEL ORAL SUSPENSION 40 MG/ML
    rufinamide oral tablet 200 mg, 400 mgBANZEL ORAL TABLET 200 MG, 400 MG
    XCOPRI oral tablets and titration/maintenance packs (25-350 mg dosing packs)XCOPRI ORAL TABLET 25 MG, 50 MG, 100 MG, 150 MG, 200 MG and titration/maintenance packs including 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg dose packs
    bimatoprost ophthalmic drops 0.01%, 0.03%bimatoprost formulations
    1–10 of 13
    1/2
    Additional listed drug groupsNDC | mixed
    FYLNETRA, NYVEPRIA, STIMUFEND, UDENYCA, ZIEXTENZOG-CSF stimulating factor subcutaneous syringes (6 mg/0.6 mL)
    leucovorin calcium oral tablets 5 mg, 10 mg, 15 mg, 25 mgleucovorin formulations
    NEUPRO transdermal patch 1 mg/24h – 8 mg/24hNEUPRO transdermal patch strengths
    ferric citrate oral tablet 210 mg (AURYXIA)AURYXIA oral tablet 210 mg iron
    VELPHORO chewable 500 mgVELPHORO chewable tablet 500 mg
    lanthanum chewable 500 mg, 750 mg, 1000 mglanthanum chewable tablet strengths
    sevelamer carbonate powder 0.8g, 2.4gsevelamer carbonate oral powder in packet
    sevelamer HCl 400 mg, 800 mgsevelamer HCl oral tablets
    FOSRENOL 750 mg, 1000 mgFOSRENOL oral powder in packet / chewable tablet strengths

    Provider responsibilities and actions

    Prior Authorization

    Prior authorization may be required

    Certain drugs listed in this step therapy criteria may require prior authorization under the pharmacy benefit; providers should verify prior authorization requirements and submit required documentation per plan procedures.

    Step Therapy

    Drugs listed for step therapy review

    This document enumerates drug classes and individual agents that are subject to step therapy review; examples include multiple antiepileptic medications (perampanel, eslicarbazepine, brivaracetam, rufinamide, cenobamate) and glaucoma agents (bimatoprost, tafluprost, VYZULTA) as listed in the policy.

    • Antiepileptic agents: perampanel (FYCOMPA), eslicarbazepine (APTIOM), brivaracetam (BRIVIACT), rufinamide (BANZEL), cenobamate (XCOPRI)
    • Glaucoma agents: bimatoprost (various concentrations/brands), tafluprost (PF), VYZULTA
    Documentation Required

    Verify coverage and benefits

    Verify member coverage and benefits before prescribing or dispensing: use the Providence Drug Search formulary tool or check the member handbook; contact Providence Customer Service for benefit verification if needed.

    • Drug Search: https://www.providencehealthplan.com/members/pharmacy-resources
    • Customer Service: 503-574-7500 or 1-800-878-4445 (TTY: 711), Mon–Fri 8 a.m.–6 p.m.
    Denial Risk

    Coverage contingent on plan rules

    Coverage of the drugs listed is subject to applicable plan restrictions and exclusions and is not a guarantee of coverage; prior authorization or member benefit verification may be required.

    Background and scope

    This policy groups multiple drug classes under a single step therapy framework. Examples include several antiepileptic medications, various glaucoma agents, phosphate binders, hematopoietic growth factors, stimulants and certain topical agents. The document lists specific formulations within those classes that are subject to step therapy, but does not provide drug-by-drug step sequences or failure definitions in the excerpt.

    Initial therapy — step definitions

    Initial therapy listing (unspecified)

    No explicit initial-step therapy agent or required first-line trial is defined in the provided excerpt.

    initial_listing: Drug appears on the step therapy listing; the document does not specify an explicit initial (first-step) agent or required trial

    Providers must consult the full policy text or the plan's Drug Search tool / formulary for plan-specific initial-step requirements and any preferred alternatives

    Step therapy details

    Drug / Drug GroupStep Therapy RequirementRequired Trial / DurationFailure Definition
    Antiepileptic medications (examples: perampanel [FYCOMPA] suspension/tablets; eslicarbazepine [APTIOM] tablets; brivaracetam [BRIVIACT] solution; rufinamide [BANZEL] suspension/tablets; cenobamate [XCOPRI] tablets and titration/maintenance packs)
    These agents are included on the plan's step therapy listing and are subject to step therapy rules under the pharmacy benefit.
    Specific required trial agents and durations are not specified in the provided text; providers must verify plan-specific step requirements through the Drug Search tool or full policy.
    Failure criteria are not defined in the provided excerpt; consult the full policy or formulary tool for failure definitions.
    Policy Summary
    PayerProvidence Health Plan
    PolicyStep therapy criteria for pharmacy-covered drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionVerify prior authorization and submit required documentation per plan procedures when prescribing drugs listed on the step therapy criteria.
    SourceLink
    On This Page
    Coverage criteria overviewListed drug formulations and code groupsProvider responsibilities and actionsBackground and scopeInitial therapy — step definitionsStep therapy details